AR011425A1 - Compuestos derivados de sulfamida, su uso, composiciones farmaceuticas que los comprenden y un procedimiento para preparar compuestos derivados de sulfamida - Google Patents
Compuestos derivados de sulfamida, su uso, composiciones farmaceuticas que los comprenden y un procedimiento para preparar compuestos derivados de sulfamidaInfo
- Publication number
- AR011425A1 AR011425A1 ARP980100227A ARP980100227A AR011425A1 AR 011425 A1 AR011425 A1 AR 011425A1 AR P980100227 A ARP980100227 A AR P980100227A AR P980100227 A ARP980100227 A AR P980100227A AR 011425 A1 AR011425 A1 AR 011425A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- sulfamide
- aralkyl
- alkyl
- derived compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compuestos derivados de sulfamida, que tienen la formula (I) en donde R1 y R2 se eligen independientemente entre hidrogeno, alquilo, alquenilo,haloalquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, heteroarilo, heteroaralquilo,heterocic lo, heterocicloalquilo, heteroalquilo, o-(alquileno)-C(O)-X, o R1 y R2 junto con el átomo de carbono al que están unidos forman un carbociclo o un heterociclo; R3 es hidrogeno, alquilo,alquenilo, haloalquilo, cicloalquilo, arilo,aralquilo, ara lquenilo, heteroarilo, heteroaralquilo, heteroalquenilo, heterocicloalquilo,heteroalquilo, (difenilmetil)-alquilo, o -(alquileno)-C(O)-X; o R3 junto con R1 o R2 y los átomos a los que están unidos forman un grupoheterocicloamino;R10 es -NR11OR12; R20 y R21 se eligen, independientemente, entre hidrogeno, alquilo, heteroalquilo, cicloalquilo, cicloalquilalquilo arilo, aralquilo,aralquenilo, heteroaralquilo, o heteroaralquenilo; o R20 y R21 junto con elátomo de nitrogeno al que están unidos forman un grupo heterocicloamino o unanillo de tetrahidropiridina o hexahidroazepina opcionalmente sustituido; o cualquiera de R20 o R21 junto con R3 forma un grupo alquileno; y sus salesfarmacéuticamenteaceptables, profármacos, isomeros individuales, y mezclas de isomeros, con la condicion de R20 y R21 junto con el átomo de nitrogeno al queestán unidos no formen un anillo morfolino: (i) cuando R1 y R3 son hidrogeno y R2 es aralquilo; o (ii)cuando R1 y R3 junto con los á tomos a los que estánunidos forman un anillo de tetrahidroisoquinolina y R2 es hidrogeno; y compuestos de formula (I) en donde R1, R2 y R3 son como se definieron antes yR10 es -OH; R20 es hidrogeno o alquilo,y R21 es cicloalquilo, arilo, aralquilo, aralquenilo, heteroarilo o heteroaralquenilo; o R20 y R21 junto con
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3671497P | 1997-01-23 | 1997-01-23 | |
US6220997P | 1997-10-16 | 1997-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR011425A1 true AR011425A1 (es) | 2000-08-16 |
Family
ID=26713422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980100227A AR011425A1 (es) | 1997-01-23 | 1998-01-20 | Compuestos derivados de sulfamida, su uso, composiciones farmaceuticas que los comprenden y un procedimiento para preparar compuestos derivados de sulfamida |
Country Status (35)
Country | Link |
---|---|
EP (1) | EP0958287B2 (es) |
JP (1) | JP3563411B2 (es) |
KR (1) | KR100377696B1 (es) |
CN (1) | CN1093125C (es) |
AR (1) | AR011425A1 (es) |
AT (1) | ATE223909T1 (es) |
AU (1) | AU730127B2 (es) |
BG (1) | BG103586A (es) |
BR (1) | BR9807508A (es) |
CA (1) | CA2278694C (es) |
DE (2) | DE69807845T2 (es) |
DK (1) | DK0958287T3 (es) |
EA (1) | EA002810B1 (es) |
ES (2) | ES2183331T3 (es) |
FR (1) | FR2758559A1 (es) |
GB (1) | GB2321641B (es) |
HR (1) | HRP980036A2 (es) |
HU (1) | HUP0000941A3 (es) |
ID (1) | ID22849A (es) |
IL (1) | IL130802A0 (es) |
IS (1) | IS5125A (es) |
IT (1) | IT1298163B1 (es) |
MA (1) | MA26467A1 (es) |
NO (1) | NO313635B1 (es) |
NZ (1) | NZ336625A (es) |
OA (1) | OA11078A (es) |
PA (1) | PA8445301A1 (es) |
PE (1) | PE57399A1 (es) |
PL (1) | PL334846A1 (es) |
PT (1) | PT958287E (es) |
TN (1) | TNSN98012A1 (es) |
TR (1) | TR199901765T2 (es) |
UY (1) | UY24854A1 (es) |
WO (1) | WO1998032748A1 (es) |
YU (1) | YU34599A (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
HN2000000052A (es) * | 1999-05-28 | 2001-02-02 | Pfizer Prod Inc | Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos. |
IL146543A0 (en) | 1999-06-04 | 2002-07-25 | Astrazeneca Ab | Inhibitors of metalloproteinases |
TR200200410T2 (tr) * | 1999-08-18 | 2002-06-21 | Warner-Lambert Company | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri. |
GT200000203A (es) | 1999-12-01 | 2002-05-24 | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas. | |
EP1274697A1 (en) * | 2000-02-21 | 2003-01-15 | AstraZeneca AB | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
AU783284B2 (en) * | 2000-02-21 | 2005-10-13 | Astrazeneca Ab | Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
US6495358B1 (en) * | 2000-04-19 | 2002-12-17 | Wichita State University | Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes |
US6897237B2 (en) | 2000-04-28 | 2005-05-24 | Shionogi & Co. Ltd. | MMP-12 inhibitors |
US6492171B2 (en) | 2000-05-16 | 2002-12-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of TERT expression |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
GB0119474D0 (en) | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
WO2003035610A1 (fr) * | 2001-10-26 | 2003-05-01 | Shionogi & Co., Ltd. | Derive de sulfonamide a effet inhibiteur sur les mmp |
ES2309313T3 (es) * | 2002-04-03 | 2008-12-16 | Topotarget Uk Limited | Compuestos del acido carbamico que comprenden un acoplamiento de piperacina como hdac inhibidores. |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
AU2003237532B2 (en) | 2002-06-12 | 2009-07-30 | Symphony Evolution, Inc. | Human ADAM-10 inhibitors |
EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
DE10344936A1 (de) * | 2003-09-27 | 2005-04-21 | Aventis Pharma Gmbh | Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen |
CN1997370B (zh) * | 2004-05-19 | 2011-06-01 | 索尔瓦药物有限公司 | N-氨磺酰-n'-芳基哌嗪类化合物在制备用于预防或治疗肥胖和相关疾病的药物中的用途 |
US7777036B2 (en) * | 2004-09-20 | 2010-08-17 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
DE102004060229A1 (de) | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
WO2007102392A1 (ja) * | 2006-03-03 | 2007-09-13 | Shionogi & Co., Ltd. | Mmp-13選択的阻害剤 |
US20100099676A1 (en) * | 2006-11-02 | 2010-04-22 | Shionogi & Co., Ltd. | Sulfonylurea derivative capable of selectively inhibiting mmp-13 |
WO2008147764A1 (en) * | 2007-05-23 | 2008-12-04 | Array Biopharma, Inc. | Mmp inhibitors and methods of use thereof |
US9920002B2 (en) | 2007-10-12 | 2018-03-20 | Basf Se | Methods for producing sulfonic acid diamides |
FR2947268B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
JP5838157B2 (ja) * | 2009-07-22 | 2015-12-24 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイThe Board Of Trustees Of The University Of Illinois | Hdac阻害剤およびそれを用いる治療法 |
CA2836487A1 (en) * | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
HUE049645T2 (hu) * | 2015-05-22 | 2020-09-28 | Chong Kun Dang Pharmaceutical Corp | Heterocikloalkil-származékok vegyületek mint szelektív hiszton deacetiláz inhibitorok és ezeket tartalmazó gyógyszerkészítmények |
WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH617318A5 (en) † | 1975-09-30 | 1980-05-30 | Ciba Geigy Ag | Microbicidal composition. |
US5140009A (en) * | 1988-02-10 | 1992-08-18 | Tap Pharmaceuticals, Inc. | Octapeptide LHRH antagonists |
US5114937A (en) * | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
IE68045B1 (en) * | 1990-05-11 | 1996-05-15 | Abbott Lab | Renin inhibitors |
WO1993006127A1 (en) * | 1991-09-17 | 1993-04-01 | Warner-Lambert Company | Novel amino acid prodrug renin inhibitors |
GB9211707D0 (en) * | 1992-06-03 | 1992-07-15 | Celltech Ltd | Peptidyl derivatives |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
RO117375B1 (ro) † | 1994-05-04 | 2002-02-28 | Novartis Ag | Derivaţi amidici n-sulfonil şi n-sulfinil de a-aminoacizi, procedee pentru prepararea acestora, compoziţie microbicidă şi metodă de control şi prevenire a infestării plantelor |
DE19507447A1 (de) † | 1995-03-03 | 1996-09-05 | Vitronic Dr Ing Stein Bildvera | Verfahren und Schaltung zum Erfassen und Weiterleiten von Videobilddaten in einem PC |
DK0861236T4 (da) * | 1995-11-13 | 2006-12-18 | Sanofi Aventis Deutschland | Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer |
DE69624081T2 (de) * | 1995-12-20 | 2003-06-12 | Agouron Pharmaceuticals, Inc. | Matrix-metalloprotease Inhibitoren |
FR2748026B1 (fr) * | 1996-04-26 | 1998-06-05 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
1998
- 1998-01-14 BR BR9807508A patent/BR9807508A/pt not_active Application Discontinuation
- 1998-01-14 EP EP98907943A patent/EP0958287B2/en not_active Expired - Lifetime
- 1998-01-14 AT AT98907943T patent/ATE223909T1/de not_active IP Right Cessation
- 1998-01-14 TR TR1999/01765T patent/TR199901765T2/xx unknown
- 1998-01-14 EA EA199900643A patent/EA002810B1/ru not_active IP Right Cessation
- 1998-01-14 ID IDW990716A patent/ID22849A/id unknown
- 1998-01-14 AU AU66140/98A patent/AU730127B2/en not_active Ceased
- 1998-01-14 ES ES98907943T patent/ES2183331T3/es not_active Expired - Lifetime
- 1998-01-14 CA CA002278694A patent/CA2278694C/en not_active Expired - Fee Related
- 1998-01-14 WO PCT/EP1998/000180 patent/WO1998032748A1/en not_active Application Discontinuation
- 1998-01-14 DE DE69807845T patent/DE69807845T2/de not_active Expired - Lifetime
- 1998-01-14 KR KR10-1999-7006632A patent/KR100377696B1/ko not_active IP Right Cessation
- 1998-01-14 IL IL13080298A patent/IL130802A0/xx unknown
- 1998-01-14 NZ NZ336625A patent/NZ336625A/en unknown
- 1998-01-14 YU YU34599A patent/YU34599A/sh unknown
- 1998-01-14 PT PT98907943T patent/PT958287E/pt unknown
- 1998-01-14 DK DK98907943T patent/DK0958287T3/da active
- 1998-01-14 PL PL98334846A patent/PL334846A1/xx unknown
- 1998-01-14 HU HU0000941A patent/HUP0000941A3/hu unknown
- 1998-01-14 JP JP53153798A patent/JP3563411B2/ja not_active Expired - Fee Related
- 1998-01-14 CN CN98803233A patent/CN1093125C/zh not_active Expired - Fee Related
- 1998-01-20 AR ARP980100227A patent/AR011425A1/es active IP Right Grant
- 1998-01-20 IT IT98MI000091A patent/IT1298163B1/it active IP Right Grant
- 1998-01-20 PE PE1998000043A patent/PE57399A1/es not_active Application Discontinuation
- 1998-01-21 FR FR9800601A patent/FR2758559A1/fr not_active Withdrawn
- 1998-01-21 MA MA24932A patent/MA26467A1/fr unknown
- 1998-01-21 PA PA19988445301A patent/PA8445301A1/es unknown
- 1998-01-22 UY UY24854A patent/UY24854A1/es not_active IP Right Cessation
- 1998-01-22 GB GB9801393A patent/GB2321641B/en not_active Expired - Fee Related
- 1998-01-22 DE DE19802350A patent/DE19802350A1/de not_active Withdrawn
- 1998-01-22 TN TNTNSN98012A patent/TNSN98012A1/fr unknown
- 1998-01-22 ES ES009800113A patent/ES2136037B1/es not_active Expired - Fee Related
- 1998-01-23 HR HR60/062,209A patent/HRP980036A2/hr not_active Application Discontinuation
-
1999
- 1999-07-19 BG BG103586A patent/BG103586A/bg unknown
- 1999-07-22 IS IS5125A patent/IS5125A/is unknown
- 1999-07-22 NO NO19993587A patent/NO313635B1/no not_active IP Right Cessation
- 1999-07-23 OA OA9900162A patent/OA11078A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR011425A1 (es) | Compuestos derivados de sulfamida, su uso, composiciones farmaceuticas que los comprenden y un procedimiento para preparar compuestos derivados de sulfamida | |
CO4790091A1 (es) | Derivados sustituidos de acido 3-sulfonil-propionico | |
AR012032A1 (es) | Compuestos derivados 3'-n-oxido, 3'-n-dimetilamina, 9-oxima eritromicina a y un proceso para su preparacion | |
ES2221440T3 (es) | Derivados de acido aminofenoxiacetico como neuroprotectores. | |
MY100846A (en) | Fungicidal pyridyl imidates | |
DK554288A (da) | Heterocycliske spiro-forbindelser og fremgangsmaade til fremstilling deraf | |
ES2053508T3 (es) | Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos. | |
ES2062501T3 (es) | Aditivos de carbamato para composiciones lubricantes. | |
ES2059804T3 (es) | Procedimiento de preparacion de eteres de oxima de propenona. | |
AR007969A1 (es) | Compuestos derivados de pirroles sustituidos, su utilizacion y composiciones farmaceuticas que contienen tales compuestos | |
ES8301927A1 (es) | Procedimiento de preparacion de acidos azabiciclohexano car-boxilicos y de sus sales | |
ES2106185T3 (es) | 3-carboxiesteroides 17-beta-sustituidos no saturados. | |
ES8604543A1 (es) | Procedimiento para la obtencion de derivados piperazinicos | |
MX9301045A (es) | Procedimiento para preparar antagonistas receptores de fibrinogeno. | |
CO4910142A1 (es) | Compuestos de furano nitrona | |
ES2062071T3 (es) | Procedimiento de preparacion de ((diarilmetoxi) alcoil)-1 pirrolidinas y piperidinas y medicamentos que las contienen. | |
ES2042030T3 (es) | Procedimiento de preparacion de una composicion para inducir y estimular el crecimiento de los cabellos y/o frenar su caida, a base de alquilpoliglicosido y de un derivado de pirimidina. | |
CO5011085A1 (es) | Fosfitos y fosfatos ciclicos derivados de eritromicina | |
EP0253502A3 (en) | Tertiary amine compounds | |
AR005123A1 (es) | Derivados de acidos carboxilicos, procedimiento para su preparracion, composiciones farmaceuticas que los comprenden y empleos de dichos derivados | |
KR910007939A (ko) | 헤테로사이클릭 화합물 및 이의 제조방법 | |
ES8202030A1 (es) | Procedimiento para la preparacion de derivados de rifamicina | |
ES2031594T3 (es) | Tioeteres aromaticos. | |
ES454285A1 (es) | Procedimiento para preparar derivados de 4-amina trans-deca-hidroquinolina. | |
ECSP961987A (es) | Inhibidores de metaloproteasa de matriz (caso ran 4070/106) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |